Álvarez-Jiménez, M, Parker, AG, Hetrick, SE, McGorry, PD, Gleeson, JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull
2011; 37: 619–30.
Gonzalez-Pinto, A, Alberich, S, Barbeito, S, Gutierrez, M, Vega, P, Ibanez, B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull
2011; 37: 631–9.
Bertelsen, M, Jeppesen, P, Petersen, L, Thorup, A, Ohlenschlaeger, J, Le Quach, P, et al. Course of illness in a sample of 265 patients with first-episode psychosis – five-year follow-up of the Danish OPUS trial. Schizophr Res
2009; 107: 173–8.
Wade, D, Harrigan, S, Edwards, J, Burgess, PM, Whelan, G, McGorry, PD. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res
2006; 81: 145–50.
Sara, G, Burgess, P, Malhi, G, Whiteford, H, Hall, W. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res
2013; 147: 216–22.
Hides, L, Dawe, S, Kavanagh, DJ, Young, RM. Psychotic symptom and cannabis relapse in recent-onset psychosis: prospective study. Br J Psychiatry
2006; 189: 137–43.
Degenhardt, L, Dierker, L, Chiu, WT, Medina-Mora, ME, Neumark, Y, Sampson, N, et al. Evaluating the drug use “gateway” theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend
2010; 108: 84–97.
Kittirattanapaiboon, P, Mahatnirunkul, S, Booncharoen, H, Thummawomg, P, Dumrongchai, U, Chutha, W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev
2010; 29: 456–61.
Gleeson, JFM, Alvarez-Jimenez, M, Cotton, SM, Parker, AG, Hetrick, S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res
2010; 119: 79–88.
Centre for Epidemiology and Evidence. Health Statistics New South Wales: NSW Population.
NSW Ministry of Health, 2012.
Yung, AR, McGorry, PD. Prediction of psychosis: setting the stage. Br J Psychiatry
2007; 191 (suppl 51): s1–8.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders.
Wing, JK, Beevor, AS, Curtis, RH, Park, SB, Hadden, S, Burns, A. Health of the Nation Outcome Scales (HoNOS). Research and development. Br J Psychiatry
1998; 172: 11–8.
Burgess, P, Trauer, T, Coombs, T, McKay, R, Pirkis, J. What does ‘clinical significance’ mean in the context of the Health of the Nation Outcome Scales?
2009; 17: 141–8.
Malla, A, Norman, R, Bechard-Evans, L, Schmitz, N, Manchanda, R, Cassidy, C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med
2008; 38: 1585–93.
Addington, DE, Beck, C, Wang, J, Adams, B, Pryce, C, Zhu, H, et al. Predictors of admission in first-episode psychosis: developing a risk adjustment model for service comparisons. Psychiatr Serv
2010; 61: 483–8.
González-Pinto, A, Alberich, S, Barbeito, S, Gutierrez, M, Vega, P, Ibáñez, B, et al. Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull
2011; 37: 631–9.
Addington, J, Addington, D. Effect of substance misuse in early psychosis. Br J Psychiatry
1998; 172 (suppl 33): 134–6.
Degenhardt, L, Roxburgh, A, McKetin, R. Hospital separations for cannabis-and methamphetamine-related psychotic episodes in Australia. Med J Aust
2007; 186: 342–5.
Curran, C, Byrappa, N, Mcbride, A. Stimulant psychosis: systematic review. Br J Psychiatry
2004; 185: 196–204.
Hermens, DF, Lubman, DI, Ward, PB, Naismith, SL, Hickie, IB. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med J Aust
2009; 190 (suppl 4): s22–5.
Strakowski, SM, DelBello, MP, Fleck, DE, Adler, CM, Anthenelli, RM, Keck, PE Jr, et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry
2007; 64: 57–64.
Baeza, I, Graell, M, Moreno, D, Castro-Fornieles, J, Parellada, M, Gonzalez-Pinto, A, et al. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res
2009; 113: 129–37.
Lambert, M, Conus, P, Lubman, DI, Wade, D, Yuen, H, Moritz, S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand
2005; 112: 141–8.
Gupta, P, Mullin, K, Nielssen, O, Harris, A, Large, M. Do former substance users with psychosis differ in their symptoms or function from non-substance users? A systematic meta-analysis. Aust NZ J Psychiatry
2013; 47: 524–37.
Rabin, RA, Zakzanis, KK, George, TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res
2011; 128: 111–6.
Yucel, M, Bora, E, Lubman, DI, Solowij, N, Brewer, WJ, Cotton, SM, et al. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull
2012; 38: 316–30.
Mueser, KT, Drake, RE, Wallach, MA. Dual diagnosis: a review of etiological theories. Addict Behav
1998; 23: 717–34.
Schnell, T, Koethe, D, Daumann, J, Gouzoulis-Mayfrank, E. The role of cannabis in cognitive functioning of patients with schizophrenia. Psychopharmacology (Berlin)
2009; 205: 45–52.
Loberg, EM, Hugdahl, K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci
2009; 3: 53.
Mathias, S, Lubman, DI, Hides, L. Substance-induced psychosis: a diagnostic conundrum. J Clin Psychiatry
2008; 69: 358–67.
Crebbin, K, Mitford, E, Paxton, R, Turkington, D. First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Soc Psychiatry Psychiatr Epidemiol
2009; 44: 710–5.
Arendt, M, Rosenberg, R, Foldager, L, Perto, G, Munk-J⊘rgensen, P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry
2005; 187: 510–5.
Durbin, J, Lin, E, Layne, C, Teed, M. Is readmission a valid indicator of the quality of inpatient psychiatric care?
J Behav Health Serv Res
2007; 34: 137–50.
Sipos, A, Harrison, G, Gunnell, D, Amin, S, Singh, SP. Patterns and predictors of hospitalisation in first-episode psychosis. Prospective cohort study. Br J Psychiatry
2001; 178: 518–23.
Petersen, L, Jeppesen, P, Thorup, A, Abel, M-B, Øhlenschlæger, J, Christensen, TØ, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ
2005; 331: 602–5.
Wade, D, Harrigan, S, Harris, MG, Edwards, J, McGorry, PD. Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis. Aust NZ J Psychiatry
2006; 40: 429–36.
Compton, MT, Gordon, TL, Goulding, SM, Esterberg, ML, Carter, T, Leiner, AS, et al. Patient-level predictors and clinical correlates of duration of untreated psychosis among hospitalized first-episode patients. J Clin Psychiatry
2011; 72: 225–32.
Warner, R. Recovery from schizophrenia and the recovery model. Curr Opin Psychiatry
2009; 22: 374–80.
Emsley, R, Chiliza, B, Asmal, L, Lehloenya, K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry
2011; 24: 114–21.
Stowkowy, J, Addington, D, Liu, L, Hollowell, B, Addington, J. Predictors of disengagement from treatment in an early psychosis program. Schizophr Res
2012; 136: 7–12.